Skip to main content
. 2011 Jun 6;286(29):25556–25563. doi: 10.1074/jbc.M111.221564

TABLE 1.

Oligonucleotides used in this work

Name Sequence (5′ → 3′)a
pri-miR-372 sense GTTACGGATCCAGATCTCTCAACCTGCGGAGAAGATAC
pri-miR-372 antisense CAGCCGAATTCTGTAAGGGACCTGTACCCAAGACAG
Cyclin A1 forward GCGGATCCTTGCCTGAGTGAGC
Cyclin A1 reverse GCGAATTCGCAGAAGCCTATGA
CDK2 forward GCGAATTCCCCAGCCCTAATCTCA
CDK2 reverse GCCTCGAGAACCCTCTTCAGCAATAA
CyclinA1-mut forward CTGAATGGATGGAGTACCAGAACTTC
CyclinA1-mut reverse GAAGTTCTGGTACTCCATCCATTCAG
CDK2-mut forward GTATTAGATGGTCATAAGTTAGCC
CDK2-mut reverse GGCTAACTTATGACCATCTAATAC
U6-RT GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAAAATATGGAAC
miR-372-RT GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACACGCTC
U6 forward TGCGGGTGCTCGCTTCGGCAGC
miR-372 forward GCCCGCAAAGTGCTGCGACAT
Reverse (universal) CCAGTGCAGGGTCCGAGGT
Actin forward CGTGACATTAAGGAGAAGCTG
Actin reverse CTAGAAGCATTTGCGGTGGAC

a Restriction sites are underlined.